Genomics

Dataset Information

0

Phase 1 trial of durvalumab (anti-PD-L1) in combination with lenalidomide in relapsed/refractory cutaneous T cell lymphoma


ABSTRACT: Phase 1 trial of durvalumab (anti-PD-L1) in combination with lenalidomide in relapsed/refractory cutaneous T cell lymphoma

PROVIDER: PRJNA1132888 | ENA |

REPOSITORIES: ENA

Dataset's files

Source:
Action DRS
SRR29731456.fastq.gz Fastqsanger.gz
SRR29731457.fastq.gz Fastqsanger.gz
SRR29731458.fastq.gz Fastqsanger.gz
SRR29731459.fastq.gz Fastqsanger.gz
SRR29731460.fastq.gz Fastqsanger.gz
Items per page:
1 - 5 of 24

Similar Datasets

2024-07-11 | GSE271668 | GEO
| PRJNA934390 | ENA
| PRJNA1200817 | ENA
| PRJNA1200818 | ENA
2023-12-31 | GSE225239 | GEO
| PRJNA1090979 | ENA
| 2088557 | ecrin-mdr-crc
| PRJNA661354 | ENA
| PRJNA661355 | ENA
2021-05-19 | GSE171003 | GEO